Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Price Down 7.1%

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) fell 7.1% during mid-day trading on Thursday . The company traded as low as $6.47 and last traded at $6.56. 327,591 shares changed hands during trading, an increase of 1% from the average session volume of 324,656 shares. The stock had previously closed at $7.06.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ATNM. StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Maxim Group upped their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.72.

Actinium Pharmaceuticals Price Performance

The stock has a market capitalization of $192.86 million, a price-to-earnings ratio of -3.58 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. On average, research analysts predict that Actinium Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Creative Financial Designs Inc. ADV boosted its stake in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares in the last quarter. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 1st quarter worth about $78,000. Finally, Brandywine Global Investment Management LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter worth about $1,033,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.